Evotec SE (FRA:EVTA)

Market Cap	1.14B
Revenue (ttm)	777.33M
Net Income (ttm)	-155.53M
Shares Out	n/a
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4,093
Open	3.100
Previous Close	3.080
Day's Range	3.100 - 3.100
52-Week Range	2.420 - 5.350
Beta	n/a
RSI	41.21
Earnings Date	Aug 13, 2025

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 4,740
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EVTA

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.